Related Experiment Video
Updated: Dec 21, 2025

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
Published on: July 29, 2012
Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling
Jacob M Wozniak1,2, Tatiana Araújo Silva3, Diane Thomas1
1Skaggs School of Pharmacy and Pharmaceutical Sciences; University of California San Diego; La Jolla, CA, United States of America.
Insights
This study reveals key host protein changes in the heart during Chagas disease (T. cruzi infection). Researchers identified potential therapeutic targets, including mitochondrial proteins and kinases, for treating chronic Chagas disease.
Area of Science:
- Proteomics and host-pathogen interactions
- Cardiovascular disease research
- Infectious disease molecular mechanisms
Background:
- Chagas disease, caused by T. cruzi infection, leads to severe cardiac complications in chronic stages.
- Current treatments for chronic Chagas disease are limited, necessitating new therapeutic targets.
- Understanding host signaling in cardiac tissue is crucial for developing effective interventions.
Purpose of the Study:
- To identify host signaling events in heart tissue during Chagas disease using quantitative proteomics.
- To define the host proteome and phospho-proteome response to T. cruzi infection in the heart.
- To uncover potential therapeutic targets for chronic Chagas disease.
Main Methods:
- Quantitative, multiplexed proteomics and phospho-proteomics on heart tissues from a Chagas disease mouse model.
- Bioinformatic analysis of kinase activity and proteomic profiles.
- Linking proteomic data to known therapeutic interventions.
Main Results:
- Proteome analysis revealed increased immune response and repression of mitochondrial proteins.
- Phospho-proteomics identified alterations in plasma membrane and cytoskeletal proteins.
- Bioinformatics indicated activation of NDRG2, JNK/p38, DYRK2, and AMPKA2 kinases, with inhibition of casein kinases.
Conclusions:
- This study provides the first molecular insight into host proteome and phospho-proteome responses in the heart during T. cruzi infection.
- Identified potential therapeutic targets include mitochondrial proteins, immune effectors, and specific kinases.
- These findings highlight pathways for further validation as drug targets for chronic Chagas disease treatment.
Abstract:
Chagas disease, the clinical presentation of T. cruzi infection, is a major human health concern. While the acute phase of Chagas disease is typically asymptomatic and self-resolving, chronically infected individuals suffer numerous sequelae later in life. Cardiomyopathies in particular are the most severe consequence of chronic Chagas disease and cannot be reversed solely by parasite load reduction. To prioritize new therapeutic targets, we unbiasedly interrogated the host signaling events in heart tissues isolated from a Chagas disease mouse model using quantitative, multiplexed proteomics. We defined the host response to infection at both the proteome and phospho-proteome levels. The proteome showed an increase in the immune response and a strong repression of several mitochondrial proteins. Complementing the proteome studies, the phospho-proteomic survey found an abundance of phospho-site alterations in plasma membrane and cytoskeletal proteins. Bioinformatic analysis of kinase activity provided substantial evidence for the activation of NDRG2 and JNK/p38 kinases during Chagas disease. A significant activation of DYRK2 and AMPKA2 and the inhibition of casein family kinases were also predicted. We concluded our analyses by linking the diseased heart proteome profile to known therapeutic interventions, uncovering a potential to target mitochondrial proteins, secreted immune effectors and core kinases for the treatment of chronic Chagas disease. Together, this study provides molecular insight into host proteome and phospho-proteome responses to T. cruzi infection in the heart for the first time, highlighting pathways that can be further validated for functional contributions to disease and suitability as drug targets.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Coronary Artery Disease II: Pathophysiology

